Reuters: Regulatory News: Isis to stop developing rheumatoid arthritis drug

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Isis to stop developing rheumatoid arthritis drug Aug 5th 2013, 11:35 Mon Aug 5, 2013 7:35am EDT Aug 5 (Reuters) - Isis Pharmaceuticals Inc said it will stop developing its experimental rheumatoid arthritis (RA) drug after a mid-stage trial showed the treatment failed to significantly improve the disease symptoms when compared to a placebo. Patients treated with the drug, called ISIS-CRPRx, had some improvements in symptoms of RA but they were not statistically significant when compared to those of patients receiving a placebo. The treatment was developed using Isis's "antisense" technology that helps a compound bind to a specific gene in order to interrupt the production of disease-causing proteins. The company already has regulatory approval for another drug that uses the same technology to treat a rare genetic disorder causing dangerously high levels of "bad" LDL (low-density lipoprotein) cholesterol. The drug, Kynamro, was approved by the FDA in January. ISIS-CRPRx was aiming to treat RA by reducing the production of C-reactive protein (CRP) -- whose levels are dramatically elevated during inflammatory disorders. The drug is also being tested in another mid-stage trial for the treatment of atrial fibrillation - a heart rhythm disorder. Data from the trial is expected in the first half of 2014, Isis said in a statement on Monday, adding that it would continue to test the drug in other diseases. Isis shares closed at $29.23 on Friday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions